May 06, 2020 6:30am EDT ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
Apr 30, 2020 6:30am EDT ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases
Apr 22, 2020 2:43pm EDT ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing
Apr 15, 2020 6:30am EDT ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity
Apr 09, 2020 6:30am EDT Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates
Feb 26, 2020 6:30am EST ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
Feb 25, 2020 6:30am EST ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants